People: StemCells Inc (STEM.W)
STEM.W on CBOE When Trading NASDAQ Global Select Market
1.88USD
21 May 2013
1.88USD
21 May 2013
Price Change (% chg)
$-0.03 (-1.57%)
$-0.03 (-1.57%)
Prev Close
$1.91
$1.91
Open
$1.90
$1.90
Day's High
$1.90
$1.90
Day's Low
$1.88
$1.88
Volume
200
200
Avg. Vol
229
229
52-wk High
$2.50
$2.50
52-wk Low
$1.42
$1.42
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
John Schwartz |
77 | 1998 | Independent Chairman of the Board |
Martin McGlynn |
65 | 2001 | President, Chief Executive Officer, Director |
Rodney Young |
49 | 2006 | Chief Financial Officer, Vice President - Finance and Administration |
Ann Tsukamoto |
59 | 2008 | Executive Vice President - Research and Development |
Stewart Craig |
50 | 2008 | Senior Vice President - Development and Operations |
Kenneth Stratton |
43 | 2007 | General Counsel |
Irving Weissman |
72 | 1997 | Director |
Eric Bjerkholt |
52 | 2004 | Independent Director |
R. Scott Greer |
53 | 2010 | Independent Director |
Ricardo Levy |
67 | 2001 | Independent Director |
Biographies
| Name | Description |
|---|---|
John Schwartz |
Dr. John J. Schwartz, Ph.D., serves as an Independent Chairman of the Board of StemCells Inc. He serves as Director of StemCells Inc. since December 1998 and was elected as Chairman of the Board at the same time. He is the former President and Chief Executive Officer of SyStemix, Inc. Dr. Schwartz is currently the president of Quantum Strategies Management Company, a registered investment advisor located in Palo Alto, California. Prior to his positions at SyStemix, he served as assistant professor, Vice President and General Counsel at Stanford University in California. Dr. Schwartz graduated from Harvard Law School in 1958 and received his Ph.D. degree in physics from the University of Rochester in 1965. |
Martin McGlynn |
Mr. Martin M. McGlynn serves as President, Chief Executive Officer, Director of StemCells Inc. Mr. McGlynn joined the company in January 2001, when he was appointed President and Chief Executive Officer of the company and of its wholly-owned subsidiaries. Mr. McGlynn was elected to the Board of Directors in February 2001. |
Rodney Young |
Mr. Rodney K.B. Young serves as Chief Financial Officer, Vice President - Finance and Administration of StemCells Inc. Mr. Rodney Young joined the company in September 2005 as Chief Financial Officer and Vice President, Finance. In November 2006 he became Chief Financial Officerand Vice President, Finance and Administration. He is responsible for functions that include Finance, Information Technology and Investor Relations. From 2003 to 2005, Mr. Young was Chief Financial Officer and a Director of Extropy Pharmaceuticals, Inc., a private biopharmaceutical company focused on developing drugs for pediatric indications. |
Ann Tsukamoto |
Dr. Ann Tsukamoto, Ph.D., serves as Executive Vice President - Research and Development of StemCells Inc. Dr. Ann Tsukamoto joined the company in November 1997 as Senior Director of Scientific Operations; was appointed Vice President, Scientific Operations in June 1998; Vice President, Research and Development in February 2002; and Chief Operating Officer, with responsibility for the company’s research and development efforts, in November 2006. In October 2008, Dr. Tsukamoto was appointed Executive Vice President, Research and Development, with responsibility for the company’s scientific and clinical development programs. |
Stewart Craig |
Dr. Stewart Craig, Ph.D., serves as Senior Vice President - Development and Operations of StemCells Inc. Dr. Stewart Craig joined the company in September 2008 with responsibilities for Development, Manufacturing, Regulatory, Quality Systems, and Facilities. From 2005 to 2008, Dr. Craig was Chief Technology Officer and Vice President of Progenitor Cell Therapy, a contract services provider for research, development, manufacture, and commercialization of cell-based therapies, prior to which he has held executive positions at Xcyte Therapies, Osiris Therapeutics and SyStemix. |
Kenneth Stratton |
Mr. Kenneth Stratton, J.D., serves as General Counsel of StemCells Inc. He joined the company in February 2007 as General Counsel, with responsibility for corporate compliance and legal affairs. In March 2008, he assumed responsibility for the Human Resources function. Prior to joining StemCells, Mr. Stratton served as Deputy General Counsel for Threshold Pharmaceuticals and as Senior Legal Counsel for Medtronic, Inc.’s Vascular business unit. |
Irving Weissman |
Dr. Irving L. Weissman, M.D., serves as Director of StemCells Inc., since September 1997. He has served as the chairman of the company’s Scientific Advisory Board since that time. He is Professor of Pathology and Developmental Biology at Stanford University, Director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine and Director of the Stanford Ludwig Center for Cancer Stem Cell Research. Among his many scientific achievements, Dr. Weissman’s laboratory was the first to discover the mammalian stem cell and the hematopoietic (blood-forming) stem cell. Dr. Weissman was also responsible for the formation of three stem cell companies: SyStemix, Inc., StemCells, Inc., and Cellerant, Inc. He is a member of the Board of Directors and the Scientific Advisory Board of StemCells. Professor Weissman received his B.S. from Montana State College in 1961 and an M.D. from Stanford University in 1965. During medical school he conducted research on thymus cell migration for nine months with Sir James Gowans at Oxford University, England. He was a postdoctoral fellow in Dr. H. S. Kaplan’s laboratory at Stanford University from 1965-1967, and was appointed as a Research Associate in the Department of Radiology upon completion of the fellowship. He was an Investigator of the Howard Hughes Medical Institute from 1990-1992. Professor Weissman is an elected member of the National Academy of Sciences (1989-present), the Institute of Medicine at the National Academy (2002-present), the American Academy of Arts and Sciences (1990-present), The American Association for the Advancement of Science (1990), the American Academy of Microbiology (1997-present), and the American Philosophical Society (2008-Present), and also served as President of the International Society of Stem Cell Research (ISSCR) from 2009 to 2010. |
Eric Bjerkholt |
Mr. Eric H. Bjerkholt serves as an Independent Director of StemCells Inc., since March 1, 2004. He is Senior Vice President, Corporate Development and Finance, and Chief Financial Officer of Sunesis Pharmaceuticals, Inc. From 2004 to 2007, he served as Senior Vice President and Chief Financial Officer of Sunesis. Mr. Bjerkholt is a member of the board of directors of Round Table Pizza, Inc. |
R. Scott Greer |
Mr. R. Scott Greer serves as an Independent Director of StemCells Inc., since June 3, 2010. He is currently a principal and managing director of Numenor Ventures LLC, which he founded in 2002 to provide funding and strategic advisory services to early stage enterprises. Mr. Greer currently serves as Chairman of Ablexis, a development stage biotechnology company, and is also on the board of Nektar Therapeutics and BAROnova. |
Ricardo Levy |
Dr. Ricardo B. Levy, Ph.D., serves as an Independent Director of StemCells Inc., since September 2001. He most recently served as Lead Director of Renegy Holdings, the successor of Catalytica Energy Systems, Inc., an environmental emissions solutions provider. Prior to his role with Renegy Holdings, Dr. Levy served as Chairman of the Board of Catalytica Energy Systems from 1995, when the company was formed as a subsidiary of Catalytica, Inc., until October 2007 when the company merged to form Renegy. Dr. Levy was a founder of Catalytica, Inc. in 1974, serving as Chief Operating Officer from 1974 until 1991, and President and Chief Executive Officer until December 2000, when Catalytica, Inc. and its subsidiary Catalytica Pharmaceuticals, Inc. were sold to DSM N.V. Before founding Catalytica, Inc., Dr. Levy was a founding member of Exxon’s chemical physics research team, and prior to that served as Chief Executive Officer of Sudamericana C.A. in Quito, Ecuador. He continues to serve as Special Advisor to the Board of Directors of Renegy Holdings, and also as a member of the Board of Directors of Accelrys Inc. (formerly Pharmacopeia, Inc.) and NovoDynamics, Inc., a private company focused on advanced image discovery. Dr. Levy holds Bachelor of Science and PhD degrees in Chemical Engineering from Stanford University, and a Master of Science Degree from Princeton University. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
John Schwartz |
-- |
Martin McGlynn |
955,507 |
Rodney Young |
436,342 |
Ann Tsukamoto |
402,444 |
Stewart Craig |
374,388 |
Kenneth Stratton |
375,945 |
Irving Weissman |
-- |
Eric Bjerkholt |
-- |
R. Scott Greer |
-- |
Ricardo Levy |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
John Schwartz |
0 | 0 |
Martin McGlynn |
1,321,000 | 2,181,905 |
Rodney Young |
450,000 | 0 |
Ann Tsukamoto |
438,250 | 640,707 |
Stewart Craig |
0 | 0 |
Kenneth Stratton |
0 | 0 |
Irving Weissman |
0 | 0 |
Eric Bjerkholt |
0 | 0 |
R. Scott Greer |
0 | 0 |
Ricardo Levy |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
SCHWARTZ JOHN J |
15,000 | $0.00 |
WEISSMAN IRVING L |
1,404 | $1.00 |
WEISSMAN IRVING L |
7,226 | $0.00 |
BJERKHOLT ERIC H |
10,000 | $0.00 |
TSUKAMOTO ANN |
22,868 | $1.69 |
MCGLYNN MARTIN M |
50,858 | $1.69 |
CRAIG STEWART |
12,440 | $1.69 |
KOSHY GEORGE |
4,388 | $1.69 |
STRATTON KENNETH BLAIR |
12,428 | $1.69 |
WEISSMAN IRVING L |
7,669 | $0.00 |
SCHWARTZ JOHN J |
12,745 | $0.00 |
PERLMUTTER ROGER M |
10,000 | $0.00 |
WEISSMAN IRVING L |
3,629 | $1.00 |
WEISSMAN IRVING L |
10,000 | $0.00 |
WEISSMAN IRVING L |
6,068 | $0.00 |
LEVY RICARDO B |
10,000 | $0.00 |
CRAIG STEWART |
856 | $2.05 |
MCGLYNN MARTIN M |
16,159 | $1.70 |
WEISSMAN IRVING L |
15,433 | $0.00 |
SCHWARTZ JOHN J |
20,680 | $0.00 |
GREER R SCOTT |
10,000 | $0.00 |
STRATTON KENNETH BLAIR |
1,834 | $0.68 |
KOSHY GEORGE |
917 | $0.68 |
CRAIG STEWART |
1,834 | $0.68 |
TSUKAMOTO ANN |
10,892 | $0.68 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
